| Title |
Cost-effectiveness analysis of ribociclib versus palbociclib in the first-line treatment of HR+/HER2– advanced or metastatic breast cancer in Spain
|
|---|---|
| Published in |
ClinicoEconomics and Outcomes Research: CEOR, November 2018
|
| DOI | 10.2147/ceor.s178934 |
| Pubmed ID | |
| Authors |
Elena Galve-Calvo, Eva González-Haba, Joana Gostkorzewicz, Irene Martínez, Alejandro Pérez-Mitru |
X Demographics
The data shown below were collected from the profile of 1 X user who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Spain | 1 | 100% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Practitioners (doctors, other healthcare professionals) | 1 | 100% |
Mendeley readers
The data shown below were compiled from readership statistics for 88 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Unknown | 88 | 100% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Student > Master | 13 | 15% |
| Researcher | 8 | 9% |
| Student > Bachelor | 8 | 9% |
| Other | 6 | 7% |
| Student > Ph. D. Student | 6 | 7% |
| Other | 13 | 15% |
| Unknown | 34 | 39% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 15 | 17% |
| Pharmacology, Toxicology and Pharmaceutical Science | 13 | 15% |
| Nursing and Health Professions | 4 | 5% |
| Economics, Econometrics and Finance | 4 | 5% |
| Social Sciences | 4 | 5% |
| Other | 11 | 13% |
| Unknown | 37 | 42% |
Attention Score in Context
This research output has an Altmetric Attention Score of 1. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 27 October 2021.
All research outputs
#20,726,252
of 25,461,852 outputs
Outputs from ClinicoEconomics and Outcomes Research: CEOR
#445
of 525 outputs
Outputs of similar age
#283,907
of 363,731 outputs
Outputs of similar age from ClinicoEconomics and Outcomes Research: CEOR
#15
of 17 outputs
Altmetric has tracked 25,461,852 research outputs across all sources so far. This one is in the 10th percentile – i.e., 10% of other outputs scored the same or lower than it.
So far Altmetric has tracked 525 research outputs from this source. They typically receive a lot more attention than average, with a mean Attention Score of 12.0. This one is in the 7th percentile – i.e., 7% of its peers scored the same or lower than it.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 363,731 tracked outputs that were published within six weeks on either side of this one in any source. This one is in the 12th percentile – i.e., 12% of its contemporaries scored the same or lower than it.
We're also able to compare this research output to 17 others from the same source and published within six weeks on either side of this one. This one is in the 11th percentile – i.e., 11% of its contemporaries scored the same or lower than it.